Skip to main content
. 2021 Feb 9;22(5):714–724. doi: 10.3348/kjr.2020.0689

Table 3. Diagnostic Performance, Sensitivity, and Specificity of CT Imaging Set and CT Plus PET/MR Imaging Set in the Follow-Up Group.

Reviewer 1 Reviewer 2
CT CT + PET/MRI P CT CT + PET/MRI P
Local recurrence
 Az 0.81 (0.64–0.92) 1.00 (0.89–1.00) 0.029 0.82 (0.66–0.93) 0.94 (0.80–0.99) 0.045
 Sensitivity (%)* 55.6 (5/9) 100.0 (9/9) 0.063 55.6 (5/9) 88.9 (8/9) 0.125
 Specificity (%)* 100.0 (26/26) 100.0 (26/26) NA 73.1 (19/26) 96.2 (25/26) 0.070
Distant lymph node metastasis
 Az 0.99 (0.89–1.00) 1.00 (0.89–1.00) 0.687 1.00 (0.89–1.00) 1.00 (0.90–1.00) 0.480
 Sensitivity (%) 66.7 (4/6) 100.0 (6/6) 1.000 83.3 (5/6) 100.0 (6/6) 1.000
 Specificity (%) 100.0 (29/29) 100.0 (29/29) NA 100.0 (29/29) 100.0 (29/29) NA
Hepatic metastasis
 Az 0.87 (0.71–0.96) 0.95 (0.82–1.00) 0.117 0.95 (0.82–1.00) 0.97 (0.85–1.00) 0.694
 Sensitivity (%) 70.6 (12/17) 94.1 (16/17) 0.125 88.2 (15/17) 100.0 (17/17) 0.500
 Specificity (%) 88.9 (16/18) 100.0 (18/18) 0.500 100.0 (18/18) 94.4 (17/18) 1.000
Peritoneal seeding
 Az 0.99 (0.88–1.00) 1.00 (0.89–1.00) 0.420 0.85 (0.69–0.95) 0.85 (0.69–0.95) 1.000
 Sensitivity (%) 80.0 (4/5) 100.0 (5/5) 1.000 80.0 (4/5) 80.0 (4/5) 1.000
 Specificity (%) 96.7 (29/30) 96.7 (29/30) NA 100.0 (30/30) 100.0 (30/30) NA
Other metastasis
 Az 0.75 (0.58–0.88) 1.00 (0.90–1.00) 0.317 0.75 (0.58–0.88) 0.75 (0.58–0.88) 1.000
 Sensitivity (%) 50.0 (1/2) 100.0 (2/2) 1.000 50.0 (1/2) 50.0 (1/2) NA
 Specificity (%) 100.0 (33/33) 100.0 (33/33) NA 100.0 (33/33) 100.0 (33/33) NA

Data were calculated using the z-test. The numbers in parentheses are 95% confidence intervals. *Calculated using the McNemar test. Numbers in parentheses are numbers of patients. Az = area under the receiver operating characteristic curve, NA = not assessable